載入中
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
一般交易時段
US$6.899
−US$0.181 · -2.56%
盤中時間採用ET。市場資料可能有所延遲。
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
日內區間
目前US$6.899
52週區間
目前US$6.899
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
60
合理估值
情緒
51
多空交錯
風險
66
高風險
動能
18
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
日內區間
目前US$6.899
52週區間
目前US$6.899
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | 40.36萬 USD | 37.84萬 USD | — | — |
| 毛利 | — | −40.36萬 USD | −37.84萬 USD | — | — |
| 研究與開發 | 1111.16萬 USD | 3103.33萬 USD | 440.35萬 USD | — | 295.59萬 USD |
| 銷售、一般及管理費用 | 1502.89萬 USD | 2212.76萬 USD | 406.11萬 USD | 95.31萬 USD | 166.26萬 USD |
| 營業費用 | 2614.05萬 USD | 5316.09萬 USD | 846.47萬 USD | 95.31萬 USD | 461.85萬 USD |
| 利息收入 | — | — | — | 494.82萬 USD | — |
| 利息支出 | 19.56萬 USD | 18.4萬 USD | 25.6萬 USD | — | 59.85萬 USD |
| 折舊和攤銷 | 50.92萬 USD | 40.36萬 USD | 37.84萬 USD | 23.08萬 USD | 9377 USD |
| 營業利益 | −2614.05萬 USD | −5356.45萬 USD | −884.3萬 USD | −95.31萬 USD | −461.85萬 USD |
| 淨利 | −2627.54萬 USD | −1011.44萬 USD | −6047.77萬 USD | 440.84萬 USD | −1559.68萬 USD |
公司資料更新於 2026年10月16日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年3月6日 | 1:50 | — | — |
已生效 2026年3月6日
1:50
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
